{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T16:48:21Z","timestamp":1784566101061,"version":"3.55.0"},"reference-count":15,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"name":"Tetraphase Pharmaceuticals, Inc."}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:p>Eravacycline is a novel, fully synthetic fluorocycline that is approved for the treatment of complicated intra-abdominal infections (cIAI) in adult patients. We report results from three studies in healthy subjects that investigated the distribution, metabolism, and excretion of intravenous (i.v.) eravacycline and the effect of a CYP3A4 inhibitor (itraconazole) and inducer (rifampin) on the pharmacokinetics (PK) of i.v.<\/jats:p>","DOI":"10.1128\/aac.01810-18","type":"journal-article","created":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T11:07:05Z","timestamp":1545044825000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":19,"title":["Mass Balance and Drug Interaction Potential of Intravenous Eravacycline Administered to Healthy Subjects"],"prefix":"10.1128","volume":"63","author":[{"given":"Joseph V.","family":"Newman","sequence":"first","affiliation":[{"name":"Tetraphase Pharmaceuticals, Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Izmailyan","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Tsai","sequence":"additional","affiliation":[{"name":"Tetraphase Pharmaceuticals, Inc., Watertown, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1515\/hsz-2013-0292"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0545-8"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01174-18"},{"key":"e_1_3_2_5_2","volume-title":"Abstr 50th Intersci Conf Antimicrob Agents Chemother","author":"Seng Yue C","year":"2010","unstructured":"Seng Yue C, Sutcliffe JA, Colucci P, Sprenger CR, Ducharme MP. 2010. Population pharmacokinetic modeling of TP-434, a novel fluorocycline, following single and multiple dose administration, abstr A1-028. Abstr 50th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02036-13"},{"key":"e_1_3_2_7_2","volume-title":"Xerava (eravacycline) for injection: full prescribing information","author":"Tetraphase Pharmaceuticals","year":"2018","unstructured":"Tetraphase Pharmaceuticals. 2018. Xerava (eravacycline) for injection: full prescribing information. Tetraphase Pharmaceuticals Inc, Watertown, MA."},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamasurg.2016.4237"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01614-13"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics3040865"},{"key":"e_1_3_2_11_2","volume-title":"Guidance for industry, safety testing of drug metabolites","author":"Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research","year":"2008","unstructured":"Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. 2008. Guidance for industry, safety testing of drug metabolites. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Washington, DC. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm079266.pdf."},{"key":"e_1_3_2_12_2","unstructured":"Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research. 2012. Draft guidance for industry: drug interaction studies\u2013study design data analysis implications for dosing and labeling recommendations. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm292362.pdf. Accessed 17 August 2016."},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx163.1359"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00275-18"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkl224"},{"key":"e_1_3_2_16_2","unstructured":"International Conference on Harmonisation. 1996. ICH harmonised tripartite guideline: guideline for good clinical practice E6(R1) current step 4 version. www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6\/E6_R1_Guideline.pdf."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01810-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01810-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:28:30Z","timestamp":1645478910000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01810-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1128\/AAC.01810-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.01810-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"2018-08-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e01810-18"}}